Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B2033 Alone or in Combination With Tislelizumab +/- Bevacizumab in Advanced Solid Tumors
NCT06427941Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label trial of BGB-B2033 in hepatocellular carcinoma (HCC), gastric cancer (GC), extragonadal yolk sac tumor and 2 more (7 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033 and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
BGB-B2033
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)extragonadal yolk sac tumorgerm cell tumor (GCT)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06427941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427941.